MX2019014597A - Inhibidores de pirazolopirimidina de pde9. - Google Patents
Inhibidores de pirazolopirimidina de pde9.Info
- Publication number
- MX2019014597A MX2019014597A MX2019014597A MX2019014597A MX2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolopyrimidine
- present
- compounds
- pde9
- pde9 inhibitors
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 2
- 229940076380 PDE9 inhibitor Drugs 0.000 title 1
- 101001117256 Drosophila melanogaster High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A Proteins 0.000 abstract 2
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 210000004227 basal ganglia Anatomy 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516903P | 2017-06-08 | 2017-06-08 | |
| US201862665840P | 2018-05-02 | 2018-05-02 | |
| PCT/US2018/036172 WO2018226771A1 (en) | 2017-06-08 | 2018-06-06 | Pyrazolopyrimidine pde9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014597A true MX2019014597A (es) | 2020-02-05 |
Family
ID=62779024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014597A MX2019014597A (es) | 2017-06-08 | 2018-06-06 | Inhibidores de pirazolopirimidina de pde9. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934294B2 (https=) |
| EP (1) | EP3634964B1 (https=) |
| JP (1) | JP2020523309A (https=) |
| KR (1) | KR20200013758A (https=) |
| CN (1) | CN111051308A (https=) |
| AU (1) | AU2018281131B2 (https=) |
| BR (1) | BR112019025813A2 (https=) |
| CA (1) | CA3064938A1 (https=) |
| MA (1) | MA53841A (https=) |
| MX (1) | MX2019014597A (https=) |
| RU (1) | RU2019144010A (https=) |
| TW (1) | TW201902898A (https=) |
| WO (1) | WO2018226771A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019144010A (ru) * | 2017-06-08 | 2021-07-13 | Мерк Шарп И Доум Корп. | Пиразолопиримидиновые ингибиторы pde9 |
| EP3893881B1 (en) * | 2018-12-12 | 2024-10-09 | Merck Sharp & Dohme LLC | Cyclobutyl pyrazolopyrimidine pde9 inhibitors |
| WO2020123272A1 (en) * | 2018-12-12 | 2020-06-18 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde9 inhibitors |
| SG11202109781QA (en) | 2019-03-08 | 2021-10-28 | Transthera Sciences Nanjing Inc | Uses of phosphodiesterase inhibitors |
| WO2021253180A1 (en) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
| CN114773256B (zh) * | 2022-03-23 | 2024-05-03 | 中国农业大学 | 一种4-氰基哌啶的合成方法 |
| CN117582909B (zh) * | 2024-01-19 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
| CN120329388B (zh) * | 2025-04-30 | 2025-09-26 | 中日友好医院(中日友好临床医学研究所) | 一种双靶点多肽及其在心衰治疗中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE960441L (en) | 1988-12-27 | 1990-06-27 | Takeda Chemical Industries Ltd | Guanidine derivatives, their production and insecticides |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| WO2002009713A2 (de) | 2000-08-01 | 2002-02-07 | Bayer Aktiengesellschaft | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
| US6770645B2 (en) | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| EP1444009A1 (en) | 2001-11-02 | 2004-08-11 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10328479A1 (de) | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
| WO2006135080A1 (ja) | 2005-06-14 | 2006-12-21 | Aska Pharmaceutical Co., Ltd. | チエノピリミジン誘導体 |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| AU2007282678B2 (en) | 2006-08-08 | 2012-09-27 | Aska Pharmaceutical Co., Ltd. | Quinazoline derivative |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP5453431B2 (ja) | 2008-09-08 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| PE20120505A1 (es) | 2009-03-31 | 2012-05-09 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a |
| AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
| AP2012006631A0 (en) * | 2010-08-12 | 2012-12-31 | Boehringer Ingelheim Int | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| SG11201502728WA (en) | 2011-10-10 | 2015-05-28 | Lundbeck & Co As H | Pde9i with imidazo pyrazinone backbone |
| TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| KR101706216B1 (ko) | 2012-04-03 | 2017-02-13 | 한화테크윈 주식회사 | 고밀도 삼차원 영상 재구성 장치 및 방법 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| US10174032B2 (en) | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| US10370336B2 (en) | 2015-07-29 | 2019-08-06 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone PDE9 inhibitors |
| WO2017019723A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
| WO2017019726A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Oxy-cyanoquinolinone pde9 inhibitors |
| RU2019144010A (ru) * | 2017-06-08 | 2021-07-13 | Мерк Шарп И Доум Корп. | Пиразолопиримидиновые ингибиторы pde9 |
-
2018
- 2018-06-06 RU RU2019144010A patent/RU2019144010A/ru unknown
- 2018-06-06 MX MX2019014597A patent/MX2019014597A/es unknown
- 2018-06-06 US US16/001,295 patent/US10934294B2/en active Active
- 2018-06-06 BR BR112019025813-2A patent/BR112019025813A2/pt not_active Application Discontinuation
- 2018-06-06 MA MA053841A patent/MA53841A/fr unknown
- 2018-06-06 WO PCT/US2018/036172 patent/WO2018226771A1/en not_active Ceased
- 2018-06-06 CA CA3064938A patent/CA3064938A1/en active Pending
- 2018-06-06 KR KR1020207000123A patent/KR20200013758A/ko not_active Withdrawn
- 2018-06-06 JP JP2019567341A patent/JP2020523309A/ja active Pending
- 2018-06-06 TW TW107119410A patent/TW201902898A/zh unknown
- 2018-06-06 CN CN201880037972.4A patent/CN111051308A/zh active Pending
- 2018-06-06 AU AU2018281131A patent/AU2018281131B2/en not_active Ceased
- 2018-06-06 EP EP18735038.4A patent/EP3634964B1/en active Active
-
2019
- 2019-10-31 US US16/670,093 patent/US11028092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11028092B2 (en) | 2021-06-08 |
| US10934294B2 (en) | 2021-03-02 |
| BR112019025813A2 (pt) | 2020-07-07 |
| RU2019144010A (ru) | 2021-07-13 |
| AU2018281131B2 (en) | 2022-01-20 |
| US20180354955A1 (en) | 2018-12-13 |
| RU2019144010A3 (https=) | 2021-10-01 |
| EP3634964B1 (en) | 2022-02-23 |
| US20200140445A1 (en) | 2020-05-07 |
| CN111051308A (zh) | 2020-04-21 |
| WO2018226771A1 (en) | 2018-12-13 |
| MA53841A (fr) | 2021-09-22 |
| TW201902898A (zh) | 2019-01-16 |
| CA3064938A1 (en) | 2018-12-13 |
| EP3634964A1 (en) | 2020-04-15 |
| JP2020523309A (ja) | 2020-08-06 |
| AU2018281131A1 (en) | 2019-12-05 |
| KR20200013758A (ko) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
| TN2014000070A1 (en) | Pyrimidine pde10 inhibitors | |
| MX2017011935A (es) | Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). | |
| WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors | |
| WO2012044561A3 (en) | 2-alkoxy pyrimidine pde10 inhibitors | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors | |
| MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
| AU2020288559A8 (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
| EA201190303A1 (ru) | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| WO2016100157A3 (en) | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | |
| MY193511A (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| PH12019501074A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| TN2018000385A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| EA201891067A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ | |
| MX2018008974A (es) | Nuevos derivados de cianoindolina sustituida como inhibidores de nik. | |
| MX2017005284A (es) | Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk). | |
| SA520420768B1 (ar) | مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية | |
| MX2019014665A (es) | Nuevos derivados de azaindolina sustituida como inhibidores de nik. | |
| WO2014150114A8 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
| EP3454860A4 (en) | 2-ANILINOPYRIMIDINE DERIVATIVES AS THERAPEUTIC ACTIVE SUBSTANCES FOR THE TREATMENT OF BRAIN CANCER | |
| MXPA05012081A (es) | Derivados de pirimidina sustituidos. | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| ZA202308795B (en) | Pro drugs of pde10 compounds | |
| AR112073A1 (es) | Inhibidores de pirazolopirimidina de pde9 |